A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).

@article{Collet2013ADC,
  title={A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).},
  author={J. P. Collet and Kurt Huber and Marc C. Cohen and Uwe Zeymer and Patrick Goldstein and Charles Pollack and Johanne Silvain and P. G. Henry and Olivier Varenne and Didier Carri{\'e} and Pierre Coste and Michael Angioi and Herv{\'e} le Breton and Guillaume Cayla and Simon Elhadad and Emmanuel Teiger and Emmanuelle Filippi and Mounir Aout and {\'E}ric Vicaut and Gilles Montalescot},
  journal={The American journal of cardiology},
  year={2013},
  volume={112 9},
  pages={1367-72}
}
Intravenous enoxaparin did not reduce significantly the primary end point (p = 0.06) compared with unfractionated heparin (UFH) in the randomized Acute Myocardial Infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up (ATOLL) trial. We present the results of the prespecified per-protocol analysis excluding patients who did not receive the treatment allocated by randomization or… CONTINUE READING